

Once-daily simeprevir (TMC435) with peginterferon/ribavirin in HCV genotype 1-infected patients in Japan: the DRAGON study

Journal of Gastroenterology

49, 138-147

DOI: [10.1007/s00535-013-0875-1](https://doi.org/10.1007/s00535-013-0875-1)

Citation Report

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Simeprevir: First Global Approval. <i>Drugs</i> , 2013, 73, 2093-2106.   | 4.9 | 31        |
| 2  | New treatments for genotype 1 chronic hepatitis C &ndash; focus on simeprevir. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 387.   | 0.9 | 17        |
| 3  | Simeprevir Capsules. <i>Hospital Pharmacy</i> , 2014, 49, 376-389.   | 0.4 | 0         |
| 4  | Simeprevir for the treatment of hepatitis C virus infection. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 241.   | 0.4 | 29        |
| 5  | Does vitamin <sc>D</sc> supplementation improve sustained virological response in cirrhotic patients with hepatitis <sc>C</sc> virus genotype 1b and high viral load?. <i>Hepatology Research</i> , 2014, 44, 1265-1267.   | 1.8 | 0         |
| 6  | Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 691-704.  | 1.3 | 9         |
| 7  | Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b. <i>Journal of Medical Virology</i> , 2014, 86, 1314-1322.  | 2.5 | 19        |
| 8  | Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 781-787.  | 0.8 | 3         |
| 9  | Treatment of Hepatitis C. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 631.  | 3.8 | 390       |
| 10 | Treatment of Infections After Hematopoietic Stem Cell Transplantation. <i>Infectious Diseases in Clinical Practice</i> , 2014, 22, 312-317.  | 0.1 | 0         |
| 11 | <sc>JSH G</sc>uidelines for the <sc>M</sc>anagement of <sc>H</sc>epatitis <sc>C</sc> <sc>V</sc>irus <sc>I</sc>nfection: A 2014 Update for <sc>G</sc>enotype 1. <i>Hepatology Research</i> , 2014, 44, 59-70.   | 1.8 | 51        |
| 12 | Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014, 49, 163-164.   | 2.3 | 5         |
| 13 | Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. <i>Journal of Gastroenterology</i> , 2014, 49, 1485-1494. | 2.3 | 7         |
| 14 | Current race in the development of DAAs (direct-acting antivirals) against HCV. <i>Biochemical Pharmacology</i> , 2014, 89, 441-452.   | 2.0 | 83        |
| 15 | Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. <i>Journal of Hepatology</i> , 2014, 61, 219-227.   | 1.8 | 135       |
| 16 | Simeprevir for the treatment of chronic hepatitis C genotype 1 infection. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 909-917.  | 2.0 | 13        |
| 17 | Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. <i>Journal of Gastroenterology</i> , 2014, 49, 941-953.   | 2.3 | 96        |
| 18 | Review article: 2014 UK consensus guidelines â€“ hepatitis C management and direct-acting anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1363-1375.   | 1.9 | 32        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Comparison of Hepatitis C Virus Testing Strategies. <i>American Journal of Preventive Medicine</i> , 2014, 47, 233-241.   | 1.6 | 16        |
| 20 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 555-566.  | 1.3 | 22        |
| 21 | Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 738-743.   | 0.4 | 15        |
| 22 | Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon- $\alpha$ 2b and) Tj ETQq1 1 0.784314 rgBT /Ov<br><i>Journal of Molecular Medicine</i> , 2014, 33, 1652-1656.  | 1.8 | 0         |
| 24 | Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace. <i>Reviews in Medical Virology</i> , 2015, 25, 254-267.  | 3.9 | 16        |
| 25 | Sustained hepatitis C virus RNA clearance accompanied by elevation of hepatitis B virus DNA after short-term peginterferon- $\alpha$ , ribavirin and simeprevir therapy in a chronic hepatitis patient having dual infection with hepatitis B and C viruses. <i>Acta Hepatologica Japonica</i> , 2015, 56, 422-427. | 0.0 | 8         |
| 26 | Alanine aminotransferase elevations during triple therapy with simeprevir, pegylated interferon plus ribavirin. <i>Acta Hepatologica Japonica</i> , 2015, 56, 567-574.  | 0.0 | 0         |
| 27 | Hepatitis C genotype 4: The past, present, and future. <i>World Journal of Hepatology</i> , 2015, 7, 2792.  | 0.8 | 41        |
| 28 | Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Na $\alpha$ -ve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0145953.   | 1.1 | 60        |
| 29 | Simeprevir: A Review of Its Use in Patients with Chronic Hepatitis C Virus Infection. <i>Drugs</i> , 2015, 75, 183-196.   | 4.9 | 23        |
| 30 | Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. <i>Journal of Medical Virology</i> , 2015, 87, 609-618.   | 2.5 | 5         |
| 31 | Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. <i>Hepatology</i> , 2015, 61, 1523-1532.   | 3.6 | 78        |
| 32 | Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis. <i>Hepatology Research</i> , 2015, 45, E89-98.   | 1.8 | 9         |
| 33 | The close linkage between the elasticity modulus measured by real-time mapping shear wave elastography and the presence of hepatocellular carcinoma in patients with a sustained virological response to interferon for chronic hepatitis C. <i>Journal of Medical Ultrasonics (2001)</i> , 2015, 42, 341-347.      | 0.6 | 1         |
| 34 | Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. <i>Molecular Diversity</i> , 2015, 19, 829-853.  | 2.1 | 8         |
| 35 | Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 4-14.   | 1.1 | 38        |
| 36 | Deconvoluting the Composition of Low-Frequency Hepatitis C Viral Quasispecies: Comparison of Genotypes and NS3 Resistance-Associated Variants between HCV/HIV Coinfected Hemophiliacs and HCV Monoinfected Patients in Japan. <i>PLoS ONE</i> , 2015, 10, e0119145.   | 1.1 | 12        |
| 37 | Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report. <i>Transplantation Proceedings</i> , 2015, 47, 809-814.  | 0.3 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 38 | Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan. <i>Journal of Medical Economics</i> , 2015, 18, 502-511.             | 1.0 | 13        |
| 39 | Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. <i>Journal of Gastroenterology</i> , 2015, 50, 238-248.     | 2.3 | 21        |
| 40 | Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. <i>Hepatology International</i> , 2015, 9, 486-507.   | 1.9 | 18        |
| 41 | New era for management of chronic hepatitis C virus using direct antiviral agents: A review. <i>Journal of Advanced Research</i> , 2015, 6, 301-310.   | 4.4 | 40        |
| 42 | Simeprevir (<sc>TMC435</sc>) once daily with peginterferon<sc>α</sc>-2b and ribavirin in patients with genotype 1 hepatitis <sc>C</sc> virus infection: The <sc>CONCERTO</sc> study. <i>Hepatology Research</i> , 2015, 45, 501-513. | 1.8 | 50        |
| 43 | Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. <i>Hepatology Research</i> , 2015, 45, 837-845.   | 1.8 | 15        |
| 44 | The prospective randomized study on telaprevir at 1500 or 2250Âmg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1. <i>Journal of Gastroenterology</i> , 2015, 50, 313-322.                         | 2.3 | 6         |
| 45 | JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. <i>Hepatology Research</i> , 2016, 46, 129-165.  | 1.8 | 55        |
| 46 | Effects of <i>ITPA</i> polymorphism on decrease of hemoglobin during simeprevir, peg<sc>α</sc>-interferon, and ribavirin combination treatment for chronic hepatitis C. <i>Hepatology Research</i> , 2016, 46, 1256-1263.            | 1.8 | 7         |
| 47 | Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naïve Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. <i>Journal of Gastroenterology</i> , 2016, 51, 390-403.          | 2.3 | 21        |
| 48 | Review article: safety and tolerability of direct<sc>α</sc>-acting anti<sc>v</sc>iral agents in the new era of hepatitis C therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 674-696.                             | 1.9 | 127       |
| 49 | Optimum predictors of therapeutic outcome in HCV patients in Pakistan. <i>Journal of Medical Virology</i> , 2016, 88, 100-108.   | 2.5 | 8         |
| 50 | The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. <i>Journal of Gastroenterology</i> , 2016, 51, 63-70.  | 2.3 | 15        |
| 51 | Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis. <i>Nephrology</i> , 2017, 22, 562-565.                                   | 0.7 | 11        |
| 52 | Direct-acting antivirals for chronic hepatitis C. <i>The Cochrane Library</i> , 2017, 2017, CD012143.  | 1.5 | 56        |
| 53 | Direct-acting antivirals for chronic hepatitis C. <i>The Cochrane Library</i> , 2017, 6, CD012143.   | 1.5 | 74        |
| 54 | Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 818-824.                                    | 0.7 | 5         |
| 55 | Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. <i>Drug Resistance Updates</i> , 2018, 37, 17-39.  | 6.5 | 155       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 56 | Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. <i>Internal and Emergency Medicine</i> , 2018, 13, 775-790.   | 1.0 | 4         |
| 57 | Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection. <i>Annals of Hepatology</i> , 2018, 17, 756-758.   | 0.6 | 1         |
| 58 | Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. <i>PLoS ONE</i> , 2018, 13, e0193112.   | 1.1 | 7         |
| 59 | New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 522-538.  | 0.4 | 38        |
| 60 | Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 596-604.                                | 0.8 | 1         |
| 61 | Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 488-495.   | 1.0 | 3         |
| 62 | Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. <i>Infection, Genetics and Evolution</i> , 2020, 84, 104451. | 1.0 | 88        |
| 63 | JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. <i>Journal of Gastroenterology</i> , 2020, 55, 640-652.                 | 2.3 | 3         |
| 64 | A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors. <i>PLoS ONE</i> , 2014, 9, e112647.   | 1.1 | 53        |
| 65 | Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 1-6.  | 0.7 | 20        |
| 66 | Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: A meta-analysis of randomized trials. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 107, 591-7.                          | 0.1 | 5         |
| 67 | Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. <i>World Journal of Gastroenterology</i> , 2015, 21, 9526.  | 1.4 | 23        |
| 68 | New treatment strategies for hepatitis C infection. <i>World Journal of Hepatology</i> , 2015, 7, 2100.   | 0.8 | 20        |
| 69 | Long-term interferon therapies improved hepatic fibrosis and prevented the recurrence of hepatocellular carcinoma in a patient with hepatitis C virus infection. <i>Acta Hepatologica Japonica</i> , 2014, 55, 399-404.   | 0.0 | 0         |
| 70 | A Case of Chronic Hepatitis C with Charcot-Marie-Tooth Disease Successfully Treated with Interferon Beta and Rivabirin Combination Therapy.. <i>Yamaguchi Medical Journal</i> , 2016, 64, 53-57.  | 0.1 | 0         |
| 71 | Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection. <i>Open Medicine Journal</i> , 2016, 3, 58-69.   | 0.5 | 0         |
| 72 | History of Treatment for Hepatitis C - In the Era When Cure Is Achieved with Oral Drugs -. <i>Juntendo Medical Journal</i> , 2019, 65, 2-11.  | 0.1 | 0         |